

# Gemini Stock Analysis Report

---

Based on the provided **Stock Detailed Analysis Report for ZYDUSLIFE.NS** (generated 2026-01-17), here is the analysis and trading recommendation.

## Step 1: Audit the Data

- **Data Present:**
    - **Price Action:** Daily, Weekly, and 15-minute candlestick charts (Pages 2, 21).
    - **Trend Indicators:** EMA 20/50/200 crossover analysis (Pages 6-7), Supertrend (Pages 10-11, 20).
    - **Momentum/Volatility:** RSI, MACD, Bollinger Bands, and Volatility Squeeze analysis (Pages 8-9, 12-15).
    - **Relative Strength:** Comparison against <sup>^</sup>CNXPHERMA (Pages 4-5).
    - **Volume:** Volume MA and Accumulation/Distribution analysis (Pages 16-19).
    - **Fundamentals:** Basic revenue/income growth metrics (Page 3).
  - **Data Missing:**
    - **Order Book/Depth:** No Level 2 data to see immediate bid/ask walls.
    - **Broad Market Context:** While Sector RS is present, broader Nifty 50 correlation is not detailed.
  - **Confidence Level: High.** The technical data is comprehensive, covering trend, momentum, volatility, and volume across multiple timeframes, allowing for a robust technical assessment.
- 

## Step 2: Analyze the Setup

### Price Structure & Trend:

- **Status: Strong Bearish.**
- The stock is trading at **INR 868.10**, which is below all key Exponential Moving Averages (20, 50, and 200).
- Page 6 explicitly flags the status as "Strong **Downtrend**."
- Crucially, the stock recently broke below the 200 EMA (INR 948.75), which is a major signal of long-term trend deterioration.
- The Supertrend is in a "Sell" state across Weekly, Daily, and 15-min timeframes (Page 20).

### Momentum & Volatility:

- **RSI:** Currently **28.35** (Oversold). While this suggests a potential bounce, oversold conditions can persist in strong downtrends.
- **Bollinger Bands:** The stock has pierced the Lower Band (INR 878.41), indicating extreme weakness.
- **Volatility Squeeze:** Page 14 indicates a "**Bearish Breakout**" occurred on 2026-01-09. This suggests the downward move has strong energy behind it and is not just a drift.
- **MACD:** Remains bearish, though the histogram shows slight signs of selling exhaustion (Page 13).

### Relative Strength:

- The stock is underperforming its sector (<sup>^</sup>CNXPHERMA) with an RS score of 45/100 (Page 4). It is not a leader.

### Confluence:

- The confluence is **negative**. Price structure, moving averages, and volatility signals all align pointing downward. The only "bullish" factor is the oversold RSI, which is unreliable as a standalone buy signal in a breakdown scenario.
-

# Gemini Stock Analysis Report

---

## Step 3: Recommendation

**Should you enter this stock now? NO.**

**Reasoning:** Buying now is "catching a falling knife." The stock has triggered a fresh volatility squeeze to the downside (**Bearish** Breakout) and is trading below the 200-day EMA. There is no confirmed support structure or reversal pattern (like a double bottom or higher low) to justify a low-risk entry.

However, given the oversold RSI (28.35), a mean-reversion bounce is possible. If you are looking for a positional trade (1-4 months), you must wait for the trend to neutralize before entering.

### Conditional Plan (Watchlist Setup)

*Keep this stock on your watchlist for a reversal play, but do not execute until the following criteria are met.*

#### Condition to Buy:

- The stock must stop making lower lows on the Daily chart.
- **Primary Trigger:** Price must close **above the EMA 20 (currently ~INR 907)**. This would indicate the short-term selling pressure has broken and the price has reclaimed the "mean."
- **Confirmation:** Ideally, RSI should cross back above 40 with rising volume.

**Entry Price: INR 912.00** (Limit order *only* after a daily close above the 20 EMA).

- **Stop Loss: INR 855.00** (Below the current swing low/Bollinger lower band area).
- **Take Profit: INR 990.00** (Targeting the resistance zone between the 200 EMA and the recent breakdown level).

*Risk/Reward Ratio for Conditional Plan: ~1.4 (Acceptable, but not elite).*

## News & Analyst Targets

Here is the latest research and information for **Zydus Lifesciences (ZYDUSLIFE)** for the week ending January 17, 2026.

### 1) Latest News for ZYDUSLIFE (Week of Jan 12 - Jan 17, 2026)

The company has had a highly active week with significant regulatory wins in the US and strategic deal closures.

#### USFDA Approval for Eltrombopag Tablets (Jan 15, 2026):

- Zydus received final approval from the USFDA to market **Eltrombopag Tablets** (generic equivalent of Novartis' *Promacta*).
- **Indication:** Treatment of thrombocytopenia (low platelet counts) in patients with chronic immune (idiopathic) thrombocytopenia (ITP) and chronic hepatitis C.
- **Market Impact:** This is a major approval; the drug has an estimated annual market size of **\$1.26 billion** in the US (IQVIA MAT Nov 2025).
- **Manufacturing:** To be produced at the group's formulation manufacturing facility in SEZ, Ahmedabad.

# Gemini Stock Analysis Report

## Completion of Agenus Acquisition & Launch of Zylidac Bio (Jan 15, 2026):

- Zydus completed the acquisition of biologics manufacturing facilities from **Agenus Inc.**
- **New Entity:** A new US-based subsidiary, **Zylidac Bio LLC**, has been established. It will operate the newly acquired facilities in Emeryville and Berkeley, California.
- **Strategic Value:** This marks Zydus' entry into the US biologics Contract Development and Manufacturing Organization (CDMO) space. Zylidac Bio will also act as the exclusive manufacturer for Agenus' Phase-3 immuno-oncology candidates.

## USFDA Approval for Menkes Disease Treatment (Jan 13, 2026):

- The USFDA approved **Zycubo (copper histidinate)**, a treatment for Menkes disease (a rare, fatal genetic disorder).
- **Significance:** This is the first FDA-approved treatment for this condition. The product was developed in collaboration with Fortress Biotech and will be marketed in the US by Zydus' subsidiary, Sentynt Therapeutics.

## 2) Upgrade/Downgrade from Brokerages

- **Jefferies: Maintained BUY.**
  - **Action:** Raised target price to **INR 1,130** (previously INR 1,120).
  - **Rationale:** The brokerage remains positive on the company's growth outlook, citing the recent approvals and the strength of its US pipeline.
- **Macquarie: Maintained BUY.**
  - **Action:** Maintained target price at **INR 1,110**.
  - **Rationale:** Continued confidence in the company's niche product launches and complex generic pipeline.

## 3) Other News Impacting ZYDUSLIFE

- **Expansion into CDMO Space:** The operationalization of **Zylidac Bio LLC** is a direct positive impact news. It diversifies Zydus' revenue stream beyond generic formulations into the high-value biologics manufacturing sector, reducing dependency on pure-play generics.
- **Regulatory Milestone:** With the Eltrombopag approval, Zydus now has **429** cumulative USFDA approvals, reinforcing its position as one of the leading Indian pharma players in the US generic market.

## 4) Latest Analyst & Brokerage Targets

Below is the summary of the most recent price targets issued or reiterated by major brokerages in January 2026.

Brokerage Firm	Rating	Target Price (INR)	Date of Report/Update
Jefferies	BUY	1,130	Jan 14, 2026
Macquarie	BUY	1,110	Jan 13, 2026
Trendlyne Consensus	Hold/Neutral	~1,015	Jan 16, 2026
Motilal Oswal	BUY	1,090	Prev. Update (Dec 25)
PhillipCapital	HOLD	970	Prev. Update (Dec 25)

*Note: The stock was trading in the range of INR 885 - INR 901 during the week, indicating a potential upside of approximately 20-25% based on the latest "Buy" ratings.*


# Stock Detailed Analysis Report

**ZYDUSLIFE.NS**

Current Price: ₹868.10

Generated: 2026-01-17 18:01

# ZYDUSLIFE.NS - 3 Year Daily Price Chart



# Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	Yes	18.68%	15.04%
Net Income	Yes	Yes	17.26%	0.28%
ROE	No	Yes	-2.93%	-10.55%
EPS	Yes	Yes	17.91%	0.86%

# Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	2.81%	2.59%
Net Income	Yes	25.27%	4.04%
ROE	Yes	17.08%	17.08%
EPS	No	12.25%	-11.77%

# ZYDUSLIFE.NS - Relative Strength Analysis

## == OVERVIEW ==:

**Benchmark Index:** ^CNXPHARMA

**Sector:** Pharma

**Classification:** **Neutral**

**RS Score:** 45.7/100

:

## == RS RATIOS ==:

**1M RS:** **0.967 [Neutral]**

**3M RS:** **0.872 [Neutral]**

**6M RS:** **0.901 [Neutral]**

**1Y RS:** **0.909 [Neutral]**

:

## == TURNAROUND ANALYSIS ==:

**Turnaround Status:** **Not Detected**

:

## SIGNAL CRITERIA::


✓ **Emerging RS:** 1M (0.967) > 3M (0.872)

✓ **Medium-term Lagging:** 6M=0.901, 1Y=0.909 ( $\leq 1.0$ )


✗ **Performance Improving:** **Not improving**

Relative Strength Analysis: ZYDUSLIFE.NS vs ^CNXPHARMA  
Classification: Neutral


Price Performance Comparison (Normalized)



RS Ratio Trends (Multiple Timeframes)



RS Composite Score Timeline






## ZYDUSLIFE.NS - EMA Crossover Summary

EMA 20:	906.97
EMA 50:	925.64
EMA 200:	948.75
Trend Status:	<b>Strong Downtrend</b>


ZYDUSLIFE.NS EMA Crossover Analysis



## ZYDUSLIFE.NS - Bollinger Bands Summary

<b>Current Price:</b>	868.10
<b>Upper Band:</b>	941.16
<b>Middle Band (SMA 20):</b>	909.78
<b>Lower Band:</b>	878.41
<b>%B:</b>	-0.1643
<b>Band Width:</b>	0.0690
<b>Status:</b>	Below Lower Band
<b>Signal:</b>	None
<b>Recent Signal 1:</b>	<b>Buy Signal at 2025-11-07 00:00:00+05:30</b>
<b>Recent Signal 2:</b>	<b>Buy Signal at 2025-12-18 00:00:00+05:30</b>
<b>Recent Signal 3:</b>	<b>Buy Signal at 2026-01-13 00:00:00+05:30</b>


ZYDUSLIFE.NS Bollinger Bands (20, 2) Analysis



## ZYDUSLIFE.NS - Supertrend Summary

Status:	<b>DOWNTREND (Sell)</b>
Supertrend Value:	927.76
Signal Identified On:	2025-09-26


Supertrend Analysis for ZYDUSLIFE.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




## ZYDUSLIFE.NS - MACD Summary

MACD Line:	-11.10
Signal Line:	-7.66
Histogram:	-3.44
Trend:	<b>Bearish</b>
Momentum:	<b>Strengthening</b>
Signal:	None

ZYDUSLIFE.NS Price



ZYDUSLIFE.NS MACD (12, 26, 9)








# ZYDUSLIFE.NS - Volatility Squeeze Summary

BB Width:	0.0690
ATR:	16.5214
Total Signals:	42
Signal 1:	BB Squeeze + ATR Contraction at 2026-01-05 00:00:00+05:30 (Pr
Signal 2:	BB Squeeze + ATR Contraction at 2026-01-06 00:00:00+05:30 (Pr
Signal 3:	BB Squeeze + ATR Contraction at 2026-01-07 00:00:00+05:30 (Pr
Signal 4:	BB Squeeze + ATR Contraction at 2026-01-08 00:00:00+05:30 (Pr
Signal 5:	<b>BB Squeeze (Bearish Breakout) at 2026-01-09 00:00:00+05:30</b>


# ZYDUSLIFE.NS - Volatility Squeeze Analysis



## ZYDUSLIFE.NS - RSI-Volume Summary

<b>Current RSI:</b>	28.35
<b>Current Volume:</b>	1052948
<b>Volume MA 20:</b>	515783
<b>Bullish Divergences:</b>	6
<b>Bearish Divergences:</b>	3
<b>Bullish Div 1:</b>	Date: 2025-11-21 00:00:00+05:30, Price: 924.30
<b>Bullish Div 2:</b>	Date: 2025-12-18 00:00:00+05:30, Price: 913.65
<b>Bearish Div 1:</b>	Date: 2025-07-01 00:00:00+05:30, Price: 991.15
<b>Bearish Div 2:</b>	Date: 2025-09-18 00:00:00+05:30, Price: 1047.85

# ZYDUSLIFE.NS RSI-Volume Divergence Analysis



# ZYDUSLIFE.NS - Volume Analysis

## == VOLUME ANALYSIS ==:

Status:

**109 Signals Detected**

:

**2025-12-18 [+]:**

**Selling Exhaustion (Bullish Div)**

**2025-12-24 [-]:**

Distribution Day

**2025-12-30 [-]:**

Distribution Day



**2026-01-07 [-]:**

Distribution Day

**2026-01-09 [-]:**

Distribution Day

# ZYDUSLIFE.NS - Volume Analysis




## Multi-Timeframe Supertrend Analysis

Timeframe	Status	Value	Last Price	Signal Date
1 Week	<b>DOWNTREND (Sell)</b>	941.91	868.1	2025-11-03
1 Day	<b>DOWNTREND (Sell)</b>	927.76	868.1	2025-09-26
15 Min	<b>DOWNTREND (Sell)</b>	874.92	868.0	2026-01-14

## Multi-Timeframe MACD Analysis

Timeframe	Trend	Momentum	Signal
1 Week	<b>Bearish</b>	Strengthening	No Signal
1 Day	<b>Bearish</b>	Strengthening	No Signal
15 Min	<b>Bearish</b>	Weakening	No Signal

ZYDUSLIFE.NS - 1 Week (Candlestick + EMAs)



ZYDUSLIFE.NS - 1 Day (Candlestick + EMAs)




ZYDUSLIFE.NS - 15 Min (Candlestick + EMAs)





Trendlyne Snapshot - ZYDUSLIFE\_main



Trendlyne Snapshot - ZYDUSLIFE\_forecaster

